Does the conventional cytogenetic risk profile still matter for prediction of venetoclax based treatment outcomes in AML?

Jan Philipp Bewersdorf; Richard M. Stone; Martin S. Tallman; Maximilian Stahl

doi:10.1080/10428194.2021.1986220

Does the conventional cytogenetic risk profile still matter for prediction of venetoclax based treatment outcomes in AML?

Jan Philipp Bewersdorf, Richard M. Stone, Martin S. Tallman, Maximilian Stahl^*

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	3318-3319
Number of pages	2
Journal	Leukemia and Lymphoma
Volume	62
Issue number	14
DOIs	https://doi.org/10.1080/10428194.2021.1986220
State	Published - 2021

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/10428194.2021.1986220

Cite this

@article{e61b491d1e4e4c1ea00f667fcfcef253,

title = "Does the conventional cytogenetic risk profile still matter for prediction of venetoclax based treatment outcomes in AML?",

author = "Bewersdorf, {Jan Philipp} and Stone, {Richard M.} and Tallman, {Martin S.} and Maximilian Stahl",

year = "2021",

doi = "10.1080/10428194.2021.1986220",

language = "English (US)",

volume = "62",

pages = "3318--3319",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",